Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
RSI speaks to The Weather Network about wildfires and climate
2017 was a record-setting year for devastating wildfires across Canada and throughout the world. The Weather Network spoke to Heather Auld, principal climate scientist about…
RSI paper on Manganese PBPK selected as a top 2017 paper
Each year the Society of Toxicology, Biological Modeling Specialty Section (BMSS) does a literature search to identify outstanding modeling papers in the field of toxicology.…
RSI and Engineers Canada develop on-line training courses
Engineers Canada has retained Risk Sciences International’s (RSI) Climate Group to develop training course modules and to deliver on-line training to Professional Engineers seeking to…
Roger Rempel joins RSI as Director of Climate Group
RSI is pleased to announce that Roger Rempel has joined us as the Director of the RSI Climate Group. Roger is a senior environmental engineer…